Prostate Cancer UK has welcomed the publication of an
independent review of the system for making new medicines available
on the NHS in Scotland.
Dr Sarah Cant, Director of Policy & Strategy at Prostate
Cancer UK, said:
"Prostate Cancer UK has long argued that the current system for
approving new medicines in Scotland requires greater transparency,
clarity and consistency. We therefore welcome the publication of
this independent review, which echoes our perspective and sets out
a number of detailed proposals for reform.
"In particular we welcome calls for the SMC to meet in public
and to introduce arrangements to allow the voice of patients to be
heard. Also - with more than a quarter of SMC approved treatments not being routinely
used on the NHS - the recommendation that health boards publish
their separate analyses of SMC appraisals appears another sensible
"It is clear there is growing support for a more open and
transparent system. We hope that the publication of this report -
and the Scottish Parliament Health and Sport Committee report to follow -
will be the catalysts required to kick-start the process. Prostate
Cancer UK will continue to work with all partners to turn these
proposals for change into a reality."